OQROGet OQRO Pro
Insider trade

Amgen (AMGN)Officer sold ~$299K

Rachna Khosla, Officer at Amgen, sold ~$299K of Amgen shares.

~$299K
Approx. value · 890 sh @ $336.24
7,082
Holds after · shares reported
Traded
Nov 12, 2025
Filed
Nov 14, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 23, 2024CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  2. Nov 19, 2024CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  3. Sep 4, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  4. Sep 11, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  5. Sep 25, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  6. Oct 24, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  7. Nov 4, 2025Company filing · Form 8-K · ResultsReported its results
  8. Nov 12, 2025 · this disclosureInsiderOfficer sold ~$299K of AMGN shares in the open market

What came next

  1. Nov 12, 2025InsiderOfficer sold ~$2.32M of AMGN shares in the open market
  2. Nov 19, 2025FDAFDA drug approval: Imdelltra
  3. Nov 20, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
  4. Dec 3, 2025Congress · 1 personMembers of Congress: 2 sales
  5. Jan 16, 2026CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  6. Jan 29, 2026CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  7. Jan 30, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
  8. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
  9. Feb 17, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  10. Feb 19, 2026InsiderOfficer sold ~$376K of AMGN shares in the open market
  11. Feb 26, 2026Insider · 1 personInsiders: 2 sales (~$20.8M)
  12. Feb 26, 2026CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  13. Mar 9, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  14. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Amgen

For Amgen, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports and 75 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AMGN page.

Other recent filings by Rachna Khosla, SVP, Business Development

The full history of Rachna Khosla, SVP, Business Development is on the profile page.

How this filing works

Other disclosures at Amgen

Everything OQRO holds on this company is on its AMGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data